Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Clear Cell Adenocarcinoma
Endometrial Mucinous Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Squamous Cell Carcinoma
Endometrial Transitional Cell Carcinoma
Endometrial Undifferentiated Carcinoma
Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm
Recurrent Uterine Corpus Carcinoma
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma|
- Incidence of adverse events as assessed by the National Cancer Institute CTCAE version 4.0 [ Time Frame: Up to 5 years ]
- Objective tumor response [ Time Frame: Up to 5 years ]
- Progression-free survival without going on a subsequent therapy against the disease [ Time Frame: At 6 months ]
- OS [ Time Frame: The duration of time from study entry to time of death or the date of last contact, assessed up to 5 years ]Characterized graphically and using descriptive statistics such as median survival.
- PFS [ Time Frame: The duration of time from study entry to time of progression or death, whichever occurs first, assessed up to 5 years ]Characterized graphically and using descriptive statistics such as median survival.
|Study Start Date:||October 2011|
|Study Completion Date:||January 2016|
|Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Experimental: Treatment (nintedanib)
Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
I. To estimate the proportion of patients with persistent or recurrent endometrial cancer, who survive progression-free without going on a subsequent therapy against the disease for at least 6 months and the proportion of patients who have objective tumor response (complete or partial), treated with BIBF 1120 (nintedanib).
II. To determine the nature and degree of toxicity of BIBF 1120 in this cohort of patients.
I. To estimate the progression-free survival (PFS) and overall survival (OS) of patients with persistent or recurrent endometrial cancer treated with BIBF 1120.
Patients receive nintedanib orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01225887
Show 59 Study Locations
|Principal Investigator:||Don Dizon||NRG Oncology|